❯ Exin lets an AI agent guide a mouse brain injection, with treatment outcomes still pending

From candidates to laboratory equipmentExin Therapeutics, a neurological drug-development startup, connected an AI agent to equipment so it could select from 19 gene therapies, choose a brain target and coordinates, and guide an injection into a live mouse with epilepsy. WIRED reported that a veterinary surgeon first opened the skull before the agent controlled the needle and injection parameters.

Humans approve irreversible stepsSafeguards included human approval of the injection plan, an emergency stop and a prohibition on changing underlying equipment-control code. The team initially used Claude Opus 5.5, which planned the procedure but declined to guide the needle. Sonnet 5 then carried out the task within the human-organized experiment.

A coordinate failure tests the setupA coordinate-system fault interrupted the procedure. The agent detected an incorrect position but could not change the code under its permissions. A separate agent helped repair it. The demonstration lasted just over an hour, versus about 45 minutes for a typical injection. Seizure outcomes have not been released, and the work has not undergone peer review.

Closing an experimental feedback loopThe demonstration extends AI’s role from reading and analysis into physical experimentation. Connecting observation with equipment control could link hypotheses, execution and feedback. What has been shown is a supervised injection workflow; treatment efficacy remains to be measured, and the demonstration was slower than conventional work.

▮ SIGNALConnecting agents to equipment creates new experimental feedback, while reliability, permissions and human safeguards directly shape the cost of running it.